Literature DB >> 10394170

Management of dialysis access-associated steal syndrome: use of intraoperative duplex ultrasound scanning for optimal flow reduction.

D Shemesh1, N J Mabjeesh, H B Abramowitz.   

Abstract

Dialysis access-associated steal syndrome (DASS) is an uncommon complication after the creation of an arteriovenous fistula and can cause irreversible ischemic damage in severe cases. Dialysis access-associated steal syndrome has been managed with the surgical reduction of the volume flow in the fistula, but this is associated with a certain incidence of access loss. Several methods are described to achieve the delicate balance between essential flow in the fistula and an adequate limb perfusion pressure. We have developed a new method with duplex ultrasound scanning to quantitate the reduction in volume flow, which will allow effective dialysis and provide adequate limb perfusion. The preoperative assessment was reproduced on the operating table with intraoperative duplex scanning. A 65-year-old woman who underwent this treatment has had resolution of her ischemic symptoms and maintains long-term patency of her dialysis access.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10394170     DOI: 10.1016/s0741-5214(99)70192-8

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  3 in total

1.  Steal syndrome complicating upper extremity hemoaccess procedures: incidence and risk factors.

Authors:  Dion Davidson; George Louridas; Randolph Guzman; John Tanner; Wendy Weighell; Jodi Spelay; Dan Chateau
Journal:  Can J Surg       Date:  2003-12       Impact factor: 2.089

2.  Distal revascularisation with interval ligation (DRIL): an experience.

Authors:  M Field; J Blackwell; A Jaipersad; M Wall; M A Silva; R H Morgan; A D Pherwani
Journal:  Ann R Coll Surg Engl       Date:  2009-04-30       Impact factor: 1.891

3.  Quantitative banding for steal syndrome secondary to arteriovenous fistulae.

Authors:  K L Jackson; K P Charpentier
Journal:  Ann R Coll Surg Engl       Date:  2010-09       Impact factor: 1.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.